COVID Meets IBD: What We Know About the Vaccine
Please Register using the form below:
Vaccines are on everyone’s mind these days, as we hope to resume a normal life without the worries of the coronavirus shortly. But what does this mean for those living with Inflammatory Bowel Disease? What do we know about the SARS-CoV-2 vaccine when it comes to IBD?
An evening hosted by the McGill IBD Research Group, Dr. Gilaad Kaplan, Professor of Medicine in the Division of Gastroenterology and Hepatology at the University of Calgary and co-chair of Crohn’s and Colitis Canada’s COVID-IBD Taskforce who, to date, have organized 20+ webinars for the IBD community, will discuss the impact of COVID-19 on those living with IBD and recent recommendations on the coronavirus vaccine.
Dr. Gilaad Kaplan is a Professor in the Cumming School of Medicine at the University of Calgary. Dr. Kaplan is a gastroenterologist who is internationally renowned for studying the global epidemiology of IBD. He is the Past Chair of the Scientific and Medical Advisory Counsel of Crohn’s and Colitis Canada (CCC), as well as the co-chair of CCC’s National COVID-IBD Task Force. He is the Chair of the American Gastroenterological Association (AGA) International Subcommittee. He was inducted as a Fellow of the AGA and named by Healio Gastroenterology as one of the top 200 leading innovators in the field of gastroenterology. In 2020, Clarivate, Web of Science named him a Highly Cited Researcher in recognition of being in the top one percent of cited researchers in the field of Medicine.